» » »

Taxol Boosts Odds of Chronic Pain Boston MA

The chemotherapy drug paclitaxel (Taxol) increases the risk of chronic neuropathic pain in breast cancer survivors, a new study shows. It included 240 women who took part in clinical trials of Taxol between 1994 and 2001. Those who experienced chemotherapy-induced peripheral neuropathy during their treatment with Taxol were three times more likely to eventually be diagnosed with chronic neuropathic pain.

Ajay D Wasan, MD
(617) 732-8510
75 Francis St
Boston, MA
Business
Brigham & Women's Hospital Anesthesiology
Specialties
Anesthesiology

Data Provided by:
Rodger Musser White, MD
(617) 726-3030
55 Fruit St
Boston, MA
Specialties
Anesthesiology
Gender
Male
Education
Medical School: Univ Of Rochester Sch Of Med & Dentistry, Rochester Ny 14642
Graduation Year: 1998

Data Provided by:
Guido Musch, MD
(617) 724-4166
32 Fruit St
Boston, MA
Specialties
Anesthesiology
Gender
Male
Education
Medical School: Univ Di Milano, Fac Di Med E Chirurgia, Milano, Italy
Graduation Year: 1993

Data Provided by:
Daniel B Carr
(617) 636-5000
750 Washington St
Boston, MA
Specialty
Pain Management

Data Provided by:
Eric Thompson Pierce
(617) 726-3030
55 Fruit St
Boston, MA
Specialty
Anesthesiology

Data Provided by:
Jennifer A Chatburn
(617) 726-3030
55 Fruit Street
Boston, MA
Specialty
Anesthesiology

Data Provided by:
Steven Andrew Barna
(617) 726-8810
55 Fruit St
Boston, MA
Specialty
Anesthesiology, Interventional Pain Management, Pain Management

Data Provided by:
Nancy L Gessner
(617) 573-3378
243 Charles St
Boston, MA
Specialty
Anesthesiology

Data Provided by:
Josephine Marie Hernandez
(617) 636-6044
750 Washington St
Boston, MA
Specialty
Anesthesiology

Data Provided by:
Nabil Ramez Fahmy
(617) 724-0342
55 Fruit St Cln 3
Boston, MA
Specialty
Anesthesiology

Data Provided by:
Data Provided by:

Taxol Boosts Odds of Chronic Pain

Provided By:

MONDAY, Nov. 30 (HealthDay News) -- The chemotherapy drug paclitaxel (Taxol) increases the risk of chronic neuropathic pain in breast cancer survivors, a new study shows.

It included 240 women who took part in clinical trials of Taxol between 1994 and 2001. Those who experienced chemotherapy-induced peripheral neuropathy during their treatment with Taxol were three times more likely to eventually be diagnosed with chronic neuropathic pain.

The study is published in the November issue of the Journal of Pain.

The findings indicate that patients treated with Taxol should be regularly monitored for neuropathic pain after their chemotherapy ends, said the researchers from the University of Texas M.D. Anderson Cancer Center.

In certain cases, patients and doctors should review the risks and benefits for continuing treatment with Taxol if a patient is likely to experience worsening neuropathy, the study authors added.

They noted that the same cellular mechanism that's altered by Taxol to kill tumors can be toxic to normal tissue.

More information

The National Pain Foundation has more about neuropathic pain.

SOURCE: American Pain Society, news release, Nov. 23, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com